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CASE REPORT
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Abstract
Purpose. To present a case study involving the use of fast neutron therapy to treat an extensive unresectable osteogenic
sarcoma arising from the left maxilla.
Patient. A 14-year-old male presented with a massive tumor producing severe distortion of his facial structures. He had
already received six courses of chemotherapy, which had reduced his pain, but had not measurably reduced the tumor.
Methods. The patient was treated with 66 MeV fast neutrons to a dose of 20.4 Gy in 13 fractions over 35 days.
Results. CT assessments indicate gradually increasing calci® cation and noticeable reduction of soft-tissue disease in the
frontal sinus, orbit and maxillary antrum.There has been some recontouring of the facial structures.The boy conducts an
active life, has no pain, and feels well. He was 17 years old at the last follow-up.
Discussion. Fast neutrons have a greater biological effectiveness than conventional photon beams. Their use has been
associated with improved chance for local control of unresectable disease.This case illustrates their effectiveness in control-
ling an unusual and aggressive osteogenic sarcoma of the facial bone and sinuses.
Introduction
Osteogenic sarcoma occurring primarily in the maxilla
is an unusual disease, one for which satisfactory treat-
ment results are difficult to obtain.
1 Multi-modality
therapy is recommended for the treatment of these
tumors, because surgery is limited for osteogenic
sarcoma arising in the maxilla, paranasal sinuses and
mandible.
2,3 In these sites, radiation therapy plays a
more prominent role as part of the de® nitive manage-
ment.
4 Neutron therapy, in particular, is associated
with an improved chance for local control of unresect-
able tumors compared to similar treatment using
conventional photon radiation therapy.
5 We report
here a case of a locally advanced osteogenic sarcoma
that has responded to chemotherapy and neutron
beam therapy.
Patient
A 14-year-old Haitian male orphan was brought to
the United States to undergo surgery on a large facial
tumor.The surgeons considered the tumor to be unre-
sectable and surgery was limited to biopsy.
Pathological diagnosis identi® ed the tumor as an
osteogenic sarcoma.The patient received six courses
of chemotherapy, which included one course of ifos-
famide with Mesna and adriamycin, four courses of
high-dose methotrexate with leucovorin rescue, and
one course of cisplatin and adriamycin by continuous
infusion. Subsequent to the completion of
chemotherapy, the patient was referred for considera-
tion of neutron beam therapy, having experienced
reduction of his pain but no measurable tumor reduc-
tion.
Physical examination demonstrated a large mass
producing severe distortion of the facial structures,
with orbital hypertelorism secondary to tumor
replacement, obliteration of the left nasal cavity, near
obliteration of the right nasal cavity, and ¯ attening of
the nose over the facial surface with extension into
the contralateral maxillary sinus.The left eye showed
signi® cant proptosis, with the eye displaced superiorly
and laterally (Fig. 1). CT demonstrated tumor
extending from the bulging left maxillary sinus into
the nasopharynx, sphenoid bone, hard palate and
nasal passageways, with nasal bone destruction and
invasion into the left orbit (Fig. 2). The tumor
measured 10.5 3 9.0 cm in greatest diameter as
measured on the CT scan.
Methods
The patient went through a full course of neutron
therapy, receiving a dose of 20.4 Gy delivered in 13
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characterized as a p(66)Be(49) neutron beam
produced by 66-MeV protons which strike a beryl-
lium target to produce a neutron beam with depth
dose characteristics similar to an 8-MV photon beam.
The beam is ® xed and the patient is treated isocentri-
cally in the seated position utilizing a specially made
chair which can be rotated. A computerized treat-
ment plan required contouring in six planes to achieve
an optimal dose distribution. Ten separate neutron
beams were utilized to ful® ll the treatment plan, which
included four anterior beams, four left posterior
oblique beams and two left anterior oblique beams.
Wedges and multiple blocks in various beams were
utilized as well.The patient completed the course of
treatment nearly on schedule, although he required
hyperalimentation and a short hospitalization during
treatment.
Results
Follow-up examinations have demonstrated reduc-
tion in the tumor mass, gradually increasing calci® ca-
tion on CT scan, and noticeable reduction of soft
tissue disease in the frontal sinus, orbit and maxillary
sinus (Fig. 3).While there is persistent proptosis, the
patient continues to have vision in the treated left
eye. At last follow-up (December 1998), the
17-year-old boy conducts an active life, participates
in sports, has no pain, and feels well.There has been
Fig. 2. Pre-treatment CT scan showing a large mass in the left maxillary sinus, bulging into the right maxillary sinus, nearly
obliterating nasal passages.
Fig. 1. Pre-treatment facial hypertelorism caused by a large
osteogenic sarcoma arising from the left maxilla..
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ated with very slow regression of the mass (Fig. 4).
On CT scan dated 12/98, the tumor mass measured
8.0 3 7.0 cm. Clinically there has been no evidence
of local disease progression and no evidence of metas-
tases.
Discussion
Osteogenic sarcoma of the facial bones and sinuses
continues to be an unusual and aggressive disease, as
80± 90% of all osteogenic sarcomas occur in the long
bones.
6 Tumors of the maxilla account for only
approximately 2± 3% of patients.
1 This represents
about one-third to one-half of osteogenic sarcomas
classi® ed as arising in the jaws, with mandibular
lesions outnumbering maxillary lesions in most
reviews.
7,8 For operable tumors, wide surgical resec-
tion is usually performed in conjunction with
chemotherapy, and radiation therapy is often
employed as well for close or positive margins, and
inoperable and recurrent tumors. Recent clinical
results have demonstrated an improving cure rate in
the treatment of surgically resectable tumors when
surgical margins are adequate.
9,10 However, the
expectation for local eradication in surgically unre-
sectable patients is poor, despite some historical results
that demonstrate that tumors of the jaw tend to have
a better prognosis than osteogenic sarcoma at other
sites, with ® rst evidence of failure more likely to be
local recurrence than distant metastases.
9,11
For this aggressive tumor, the radiobiological effect
of neutron therapy compared to conventional photon
Fig. 3. Post-treatment CT scan January 1998 demonstrating facial recontouring, reduction of tumor, and calci® cation within the
tumor.
Fig. 4. Post-treatment photograph demonstrating decreased
hypertelorism and reduction of facial tumor.
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control of the tumor.
12 Historically, local control for
unresectable and/or inoperable osteogenic sarcoma has
been greater than 40% in patients (all age groups)
treated at the Midwest Institute for Neutron Therapy
at Fermilab.
13 Fast neutrons may be considered the
best radiation quality used in the treatment of osteo-
genic sarcomas, as well as other sarcomas of soft tissue
and bone in which the local control rate is 53%.
12
Worldwide data from earlier neutron therapy reports
indicate a local control rate of 40± 60% for sarcomas of
bone and soft tissue, which compares favorably with
the 21% local control rate reported utilizing photon
irradiation.
5 For high-energy fast neutron beams, the
likelihood and severity of soft tissue complications are
similar to those of conventional photon therapy. In
addition, there is approximately 25% less dose absorp-
tion in bony cavities due to the low neutron kerma in
bone, thus lessening the risk of late injury to normal
bone compared with conventional photon therapy.
14
Some early studies using low-energy fast neutron beams
found unacceptable complications.
15These low-energy
beams are no longer recommended for treatment
purposes, and all such facilities in the United States
have been closed.
At present, there are only three high-energy fast
neutron therapy facilities in the United States and a
limited number of installations worldwide.
Consequently, this treatment modality is of limited
accessibility to patients, but nevertheless should not
be overlooked as a possible way to improve control in
appropriate cases.
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